GYRE GYRE THERAPEUTICS, INC.

8-K Current Report

Filed: March 12, 2026

Health Care

Pharmaceutical Preparations

GYRE THERAPEUTICS, INC. (GYRE) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.

Reported 8-K Items
1 item

Item 7.01: Regulation FD Disclosure

AI Filing Analysis
8-K

Item 7.01 · Regulation FD Disclosure

• F351 (liver fibrosis) targeted at $400-600M revenue within 5 years; upside via off-label MASH use (~40% MASH mix in HBV practices)
• ETUARY® (lung fibrosis) expected to sustain ~$100M revenue with 30-40% of current sales from rheumatoid disease channel

+3 more insights

Other GYRE THERAPEUTICS, INC. 8-K Filings

8-K Mar 12, 2026

8-K Mar 2, 2026

Get deeper insights on GYRE THERAPEUTICS, INC.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.